Cost-utility analysis of add-on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China

IF 3.7 2区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS ESC Heart Failure Pub Date : 2025-03-11 DOI:10.1002/ehf2.15272

Lu Wang, Yinglin Wang, Quan Zhao

{"title":"Cost-utility analysis of add-on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China","authors":"Lu Wang, Yinglin Wang, Quan Zhao","doi":"10.1002/ehf2.15272","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>The study aimed to analyse the cost-utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective.</p>\n </section>\n \n <section>\n \n <h3> Methods and results</h3>\n \n <p>From the perspective of the healthcare payer, a Markov model was established to estimate the cost-utility of adding QLQX capsules to standard treatment versus standard treatment. A 19-year lifetime horizon was chosen with a 3-month cycle in the base case analysis. The discount rate of cost and utility is 5%. Total costs and quality-adjusted life years (QALYs) for QLQX and standard treatment were simulated over a 19-year lifetime horizon by the Markov model using TreeAge Pro 2022. The incremental cost-utility ratio (ICUR) was compared with the willingness-to-pay thresholds (the GDP per capita). The one-way sensitivity analysis and probability sensitivity analysis were conducted. Over a 19-year lifetime horizon, the mean total costs in the QLQX group and standard treatment group were 56 151.75 <i>CNY</i> and 30 099.69 <i>CNY</i>, respectively. The QALYs in the QLQX group were also greater than those in the standard treatment group (4.63 <i>QALYs</i> vs. 4.17 <i>QALYs</i>). The ICUR was 57 381.85 <i>CNY</i> per QALY, which was lower than the willingness-to-pay threshold (89 358 <i>CNY</i>). The one-way and probability sensitivity analyses showed that the results were robust. The inputs with the largest impact on ICUR were the cardiovascular mortality in both groups. At a willingness-to-pay threshold of 89 358 CNY, adding QLQX capsules to standard treatment was preferred over standard treatment alone in 51.10% of the 1000 PSA samples.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This cost-utility analysis suggested that adding QLQX capsules seems to be cost-effective of heart failure with a reduced ejection fraction patients from the healthcare payer's perspective in China. Future studies of QLQX capsules based on different economic systems and medical environments were also needed.</p>\n </section>\n </div>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 4","pages":"3095-3102"},"PeriodicalIF":3.7000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15272","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The study aimed to analyse the cost-utility of Chinese patent medicine Qili Qiangxin (QLQX) capsules in heart failure with a reduced ejection fraction from the healthcare payer's perspective.

Methods and results

From the perspective of the healthcare payer, a Markov model was established to estimate the cost-utility of adding QLQX capsules to standard treatment versus standard treatment. A 19-year lifetime horizon was chosen with a 3-month cycle in the base case analysis. The discount rate of cost and utility is 5%. Total costs and quality-adjusted life years (QALYs) for QLQX and standard treatment were simulated over a 19-year lifetime horizon by the Markov model using TreeAge Pro 2022. The incremental cost-utility ratio (ICUR) was compared with the willingness-to-pay thresholds (the GDP per capita). The one-way sensitivity analysis and probability sensitivity analysis were conducted. Over a 19-year lifetime horizon, the mean total costs in the QLQX group and standard treatment group were 56 151.75 CNY and 30 099.69 CNY, respectively. The QALYs in the QLQX group were also greater than those in the standard treatment group (4.63 QALYs vs. 4.17 QALYs). The ICUR was 57 381.85 CNY per QALY, which was lower than the willingness-to-pay threshold (89 358 CNY). The one-way and probability sensitivity analyses showed that the results were robust. The inputs with the largest impact on ICUR were the cardiovascular mortality in both groups. At a willingness-to-pay threshold of 89 358 CNY, adding QLQX capsules to standard treatment was preferred over standard treatment alone in 51.10% of the 1000 PSA samples.

Conclusions

This cost-utility analysis suggested that adding QLQX capsules seems to be cost-effective of heart failure with a reduced ejection fraction patients from the healthcare payer's perspective in China. Future studies of QLQX capsules based on different economic systems and medical environments were also needed.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

七力强心胶囊治疗慢性心力衰竭伴射血分数降低的成本-效用分析。

目的：从医疗保健支付者的角度分析中成药七力强心胶囊治疗心力衰竭伴射血分数降低的成本-效用。方法与结果：从医疗保健支付者的角度，建立马尔可夫模型来估计标准治疗与标准治疗中添加QLQX胶囊的成本-效用。在基本案例分析中，选择了19年的生命周期和3个月的周期。成本和效用的贴现率为5%。使用TreeAge Pro 2022，通过马尔可夫模型模拟了QLQX和标准治疗的总成本和质量调整生命年（QALYs）在19年的生命周期内。将增量成本效用比（ICUR）与支付意愿阈值（人均GDP）进行比较。进行单因素敏感性分析和概率敏感性分析。在19年的生命周期中，QLQX组和标准治疗组的平均总成本分别为56 151.75元人民币和30 099.69元人民币。QLQX组的QALYs也高于标准治疗组（4.63 QALYs vs. 4.17 QALYs）。ICUR为57 381.85元/ QALY，低于支付意愿阈值（89 358元）。单因素和概率敏感性分析表明，结果是稳健的。对ICUR影响最大的输入是两组的心血管死亡率。在支付意愿阈值为89 358元时，在1000份PSA样本中，51.10%的患者更倾向于在标准治疗中加入QLQX胶囊，而不是单独进行标准治疗。结论：本成本效用分析表明，从中国医疗保健支付者的角度来看，添加QLQX胶囊似乎对射血分数降低的心力衰竭患者具有成本效益。在不同的经济体系和医疗环境下，还需要进一步研究QLQX胶囊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

7.00

自引率

7.90%

发文量

461

审稿时长

12 weeks

期刊介绍： ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.